TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04758169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Homestead Food Production
Description: Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
Study: NCT04678271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFIX-OB Quality Improvement Package
Description: Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
Study: NCT04700371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interwoven stent
Description: Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser-cut stent
Description: Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Study: NCT06088732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Session
Description: 30 min cycling on bicycle ergometer at 60% peak power output

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Session
Description: 30 min cycling on bicycle ergometer at 60% peak power output

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: A single oral dose of Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: A single oral dose of Ibuprofen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: Resting for 30 min in chair

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: Resting for 30 min in chair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT04218825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlormethine gel
Description: Gel to be applied to all skin areas affected by MF-CTCL
Study: NCT05783492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: 10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
Study: NCT05193851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ricolinostat
Description: This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period.
Study: NCT04936204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ConnettivinaBio Plus cream
Description: The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConnettivinaBio cream
Description: The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
Study: NCT06362395

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Description: Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Description: Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
Study: NCT05685394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg P.O. daily
Study: NCT05278936

Intervention type: OTHER
Group type: OTHER
Intervention: The cataract surgery and the anterior vitrectomy
Description: Surgical
Study: NCT05713968

Intervention type: OTHER
Intervention: patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
Description: patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM

Intervention type: OTHER
Intervention: patients with EAT-10 lower than 3 or frailty questionnaire lower than 2
Description: patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
Study: NCT06380348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101 Injection
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib tablet
Description: Osimertinib 160mg once po everyday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed injection
Description: Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
Study: NCT05226143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel Cream
Description: Gel Cream
Study: NCT06165861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (with VR-G)
Description: Watching video with using VR-G before undergoing open heart surgery
Study: NCT05823610

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
Study: NCT06097325

Intervention type: DIAGNOSTIC_TEST
Intervention: Clance impostor phenomenon scale
Description: The CIPS will be used as diagnostic test in the online survey.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clance impostor phenomenon scale
Description: The CIPS will be used as diagnostic test in the online survey.

Intervention type: DIAGNOSTIC_TEST
Intervention: Maslach Burnout Inventory for Medical Professional
Description: The MBI-HSS-MP will be used as diagnostic test in the online survey.

Intervention type: DIAGNOSTIC_TEST
Intervention: Maslach Burnout Inventory for Medical Professional
Description: The MBI-HSS-MP will be used as diagnostic test in the online survey.
Study: NCT05410977

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed
Study: NCT04907812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved
Study: NCT04979962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EW10-EC02 (Endoscopy Support Program)
Description: EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
Study: NCT05211245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic ultrasound
Description: Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultrasound
Description: Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
Study: NCT05702372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracker made by wheat flour
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracker made by rye flour
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracker made by sunflower flour
Description: Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT04635345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Vibrator - patient-administered.
Description: Patient provided with external vibrator for self-use, as well as vaginal dilators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
Study: NCT04939532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN)
Description: Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty.
Study: NCT06380751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: CDK4/6 Inhibitor
Study: NCT05572541

Intervention type: DIAGNOSTIC_TEST
Intervention: Fonseca questionnaire
Description: Fonseca questionnaire for the evaluation of temporomandibular dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: Fonseca questionnaire
Description: Fonseca questionnaire for the evaluation of temporomandibular dysfunction
Study: NCT05784870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shengxuening Tablet
Description: Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous succinate
Description: Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
Study: NCT05133206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advice on fasting before the procedure
Description: Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
Study: NCT04829461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal
Description: Procedure using a single-use cystoscope for stent removal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care reusable cystoscope used for stent removal
Description: Procedure using a reusable cystoscope for stent removal
Study: NCT04679714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (PLAR Implant and Delivery System)
Description: The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
Study: NCT04378439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Description: First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Description: First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP.
Study: NCT06380751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 Inhibitor
Study: NCT04378439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP.
Study: NCT05068388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-Endoxifen
Description: Z-Endoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-Endoxifen
Description: Z-Endoxifen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06380751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: CDK4/6 Inhibitor